SLRX Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -- compared to Salarius Pharmaceuticals, Inc.'s net margin of 49.9%. Salarius Pharmaceuticals, Inc.'s return on equity of -316.09% beat CorMedix, Inc.'s return on equity of 95.25%.

Salarius Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 44701.82%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than CorMedix, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than CorMedix, Inc..

Salarius Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.225% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Salarius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Salarius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Salarius Pharmaceuticals, Inc.'s net income of -$873.5K is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Salarius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals, Inc. is -- versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humacyte, Inc. has a net margin of -- compared to Salarius Pharmaceuticals, Inc.'s net margin of -2325.37%. Salarius Pharmaceuticals, Inc.'s return on equity of -316.09% beat Humacyte, Inc.'s return on equity of --.

Salarius Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 44701.82%. On the other hand Humacyte, Inc. has an analysts' consensus of $7.86 which suggests that it could grow by 504.4%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Humacyte, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Humacyte, Inc..

Salarius Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.225% less volatile than S&P 500. In comparison Humacyte, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Salarius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humacyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Humacyte, Inc. pays out -- of its earnings as a dividend.

Salarius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Humacyte, Inc. quarterly revenues of $753K. Salarius Pharmaceuticals, Inc.'s net income of -$873.5K is higher than Humacyte, Inc.'s net income of -$17.5M. Notably, Salarius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Humacyte, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals, Inc. is -- versus 118.43x for Humacyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Salarius Pharmaceuticals, Inc.'s net margin of 31.72%. Salarius Pharmaceuticals, Inc.'s return on equity of -316.09% beat Eli Lilly & Co.'s return on equity of 106.26%.

Salarius Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 44701.82%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Salarius Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.225% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Salarius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Salarius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Salarius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Salarius Pharmaceuticals, Inc.'s net income of -$873.5K is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Salarius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals, Inc. is -- versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Vor Biopharma, Inc. has a net margin of -- compared to Salarius Pharmaceuticals, Inc.'s net margin of --. Salarius Pharmaceuticals, Inc.'s return on equity of -316.09% beat Vor Biopharma, Inc.'s return on equity of --.

Salarius Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 44701.82%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $50.33 which suggests that it could grow by 504.24%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Vor Biopharma, Inc..

Salarius Pharmaceuticals, Inc. has a beta of 0.398, which suggesting that the stock is 60.225% less volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Salarius Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.

Salarius Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Vor Biopharma, Inc. quarterly revenues of --. Salarius Pharmaceuticals, Inc.'s net income of -$873.5K is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, Salarius Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals, Inc. is -- versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.